The Food and Drug Administration's most polarizing official may be leaving, but that's no guarantee that the agency is about to undergo what its critics say is a needed course-correction. Why it ...

Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes this year.

A system that allows drug makers to profit from restricted access will never liberalize on its own—and patients will continue to bear the cost.